ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured

Dr Kiyoshi Yoshimura
The two leading immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), delivered outstanding trial results at this year’s American Society of Clinical Oncology (ASCO) meeting, but these anti-PD-1 antibodies will not necessarily dominate the market with anti-PD-L1 antibodies possibly outstripping them with combination opportunities, immunotherapy researcher Kiyoshi Yoshimura said. In the ninth and last of this series, we spoke with Dr Yoshimura about his take on the current and future immuno-oncology landscape.

PIII clinical trial results presented at the ASCO meeting showed that Opdivo by Bristol-Myers Squibb (BMS) demonstrated superior efficacy over docetaxel against both adenocarcinoma (non-squamous cell carcinoma) and squamous carcinoma.

News Calendar